Cytokine Release Syndrome
Conditions
Keywords
COVID-19
Brief summary
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
Detailed description
This clinical trial will utilize a 3+3 enrollment design with sentinel approach.
Interventions
BIOLOGICALST266
1X ST266
Sponsors
IQVIA Biotech
Noveome Biotherapeutics, formerly Stemnion
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Males and non-pregnant/non-breastfeeding females age 18-70 years of age. 2. Laboratory confirmed SARS-CoV-2 infection determined by PCR or other commercial/public health assay (test results must be obtained within 7-days of the Screening Visit). 3. BMI between 18 and 39 inclusive, with a maximum weight of 150 kg (330lbs). 4. Asymptomatic or mildly symptomatic COVID-19 positive subject with a score of 1 or 2 on the WHO 7-point ordinal scale. 5. Subjects with pulse oximetry of \> 94% on room air 6. Subjects have controlled blood pressure of \< 160/100 mmHg or systolic BP \> 90 mmHg (or 20 mmHg less than usual range, whichever is higher) 7. Subjects with pulse \< 120 bpm 8. Willingness and ability to comply with study-related procedures and assessments. 9. If female, subjects must use an effective method of birth control or abstain from sexual relations with a male partner (unless has undergone tubal ligation or is 1 year postmenopausal) for their duration of study participation. 10. If male, subjects must use an effective method of birth control or abstain from sexual relations with a female partner (unless has undergone a vasectomy and it has been more than 6 months) for their duration of study participation. 11. Subject or subject's legal representative provides written consent prior to the initiation of any Screening or study specific procedures.
Exclusion criteria
1. Subjects requiring immediate admission to the hospital due to complications of COVID-19 infection. 2. Subject has an untreated active bacterial, fungal, viral or other infection not related to COVID-19 infection. 3. Subjects with chronic lung diseases of any etiology including idiopathic pulmonary fibrosis, Tuberculosis, COPD, persistent asthma, and pulmonary hypertension. 4. Subjects with a severe history of cardiac disease (such as congestive heart failure, coronary artery disease, cardiac arrhythmia) 5. Subjects with a history of neurological disorders (such as epilepsy, stroke, encephalopathy, Guillain-Barré syndrome) 6. Subjects with D-dimer \> 2 ug/mL 7. Subjects with a history of coagulopathy or currently taking anti-coagulation medication 8. Subjects with PTT ≥ 100s or INR ≥ 2.75 9. Malignancy in the last 5 years (except successfully treated basal cell carcinoma). 10. Stage 4 severe chronic kidney disease or requiring dialysis (i.e., eGFR \< 30). 11. Subjects with a reactive or positive screening test result For Hepatitis A virus immunoglobulin M (HAV IgM), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus Antibody (HCVAb) or Human Immunodeficiency Virus Antibody (HIVAb). 12. TBIL\> 2×ULN, ALT \> 3×ULN, AST\> 3×ULN, or ALP\> 3×ULN. 13. Neutrophils \<1000/mm3, PLT\<50×10\^9/L, or HGB\<8g/dL 14. Previous participation in any other interventional clinical trial for the treatment for COVID-19. 15. Subject actively participating in any other clinical study (with the exception of observational studies where there is no intervention with an investigational product or device) 16. Use of anti-cancer or immunomodulatory biological drug or kinase inhibitor (e.g., tocilizumab, sarilumab) or, JAK inhibitors (within 30 days of enrollment or five times the half-life \[whichever is longer\]). 17. Chronic glucocorticosteroid use equivalent to daily oral prednisone \> 10 mg per day (10 mg oral prednisone every other day is allowed). 18. Live (live-attenuated) vaccines are not permitted within 2 weeks prior to enrollment or during the study treatment and safety follow-up periods, including the SARS-CoV-2 vaccine (with the exception of the Flu vaccine which is allowed at any time) 19. Subject is pregnant or breastfeeding or plans to become pregnant within 12 months. 20. Subjects with a history of alcohol or drug abuse, or the use of illicit drugs within the 12 months prior to Screening or use of medical marijuana within 1 month prior to Screening. 21. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and Severity of Treatment-Emergent Adverse Events | 3 months | Determine the incidence and severity of treatment-emergent adverse events related to the IV administration of ST266 based on findings from physical examinations, laboratory evaluations, vital signs, and ECG measurements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulse Oximetry | 14 days | Percent improvement in pulse oximetry from Baseline to Day 14 |
| Fever | 14 days | Time to resolution of fever |
| Clinical Status on Ordinal Scale | 14 days | Improvement or absence of worsening in clinical status on WHO 7-point ordinal scale from baseline to Day 14 |
Other
| Measure | Time frame | Description |
|---|---|---|
| IL- 1β at Day 14 | 14 days | Change in IL- 1β from Baseline through Day 14 |
| TNFα at Day 6 | 6 days | Change in TNFα from Baseline through Day 6 |
| IL-6 at Day 14 | 14 days | Change in IL-6 from Baseline through Day 14 |
| IL- 1β at Day 6 | 6 days | Change in IL- 1β from Baseline through Day 6 |
| IL-6 at Day 6 | 6 days | Change in IL-6 from Baseline through Day 6 |
| TNFα at Day 14 | 14 days | Change in TNFα from Baseline through Day 14 |
Countries
United States
Outcome results
None listed